You are here

Home » Content

TİP 2 DİABETİK HASTALARDA NEFROPATİNİN BAŞLANGİÇ DÖNEMİNDE PLAZMA ENDOTELİN-I DÜZEYLERİ

ENDOTHELÎN 1 LEVELS IN TYPE II DIABETIC PATIENTS DURING THE INITIAL PHASE OF NEPHROPATHY

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1994

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Nefropathy is a common complication of diabetes mellitus. During the initial phase of nephropathy there is an increase in renal plasma flow and filtration fraction. Vasoactive amines are probably involve in the of diabetic nephropathy. Tlıis study was planned to show the role of Endothelin 1 on diabetic nephropathy during the microalbuminuria phase in Type II diabetic patients. 16 Type II diabetic patients with mild to moderate hypertension and microalbuminuria were included in the study population. Patients were treated with enalapril maleate and dose adjustments were made according to blood pressure control. Plasma Endothelin 1 levels were studied at the beginning and after an average follow up of 3.4 months and compared with the healthy control group. Tlie initial microalbuminuria level of 49.1±35.5mg/day decreased to 18.8±15.9mg/day (p<0.005), the initial systolic blood pressure 162 + 19.4 mmHg decreased to 130.6±12.4 mmHg (p<0.001) and the initial diastolic blood pressure 84.1±10.5 mmHg decreased to 76.9±8.5 mmHg (p<0.05) all being statistically significant. TJiere were no statistically significant changes in Haemoglobin Ale levels and lipid profiles during the study. Plasma renin activity was 1.97±2.3ng/ml/hour initially, 6.40±8.98ng/ml/ hour at the and of the study, and 3.44±2.52 ng/ml/hour is the control group, being statistically insignificant. Tlie plasma endothelin 1 level was 7.55±7.82 pmol/ml initially, 9.20±4.34 pmol/ml at the end of the study, and 14.39±6.01 pmol/ml in the control group. There was a statistical difference between the patients initial levels and control group levels (p<0.01). As a result, in Type II diabetic patients, during the microalbuminuria phase of nephro-pathy, endothelin levels were found to be low. Although there was a significant decrease in microalbuminuria following enalapril maleate therapy there was no change in endot- helin 1, the hypothesis supporting that endothelin is not involved in the pat-hogenesis of nephropathy in Typell diabetic patients.
Bookmark/Search this post with
Abstract (Original Language): 
Diabetik hastalarda nefropati sık görülen bir komp-likasyondur. Nefropati gelişiminde erken dönemde renal plazma akımı ve filtrasyon fraksiyonunun arttığı bilinmektedir. Bu olayda çeşitli vazoaktif maddelerin rol oynadığı düşünülmektedir. Bu çalışma Tip 2 Diabetik hastalarda, nefropatinin mikroalbüminüri döneminde Endotelin V in rolünü araştırmak amacıyla yapılmıştır. Çalışmaya 16 Tip 2 Diabetik hasta alındı. Hastala¬rın mikroalbüminüri ve hafif, orta şiddette hipertansi¬yonları vardı. Hastalara kan basınçlarına göre dozu ayarlanmak üzere enalapril maleat tedavisi başlandı. Çalışma başlangıcında ve ortalama 3.4 aylık takip so¬nunda alınan örneklerden endotelin 1 düzeyleri çalışıl¬dı ve yaş cins uyumlu sağlıklı kontrol grubu ile karşı¬laştırıldı. Tedavi başlangıcında ortalama 49.1 ±35.5 mg/gün olan mikroalbüminüri, enalapril tedavisi ile 18.8±15.9 mg/gün değerine düştü (p<0.005). Sistolik kan basıncı 162 ±19.4 mmHg iken tedavi ilel30±12.4 mmHg (p<0.001) ve diastolik kan basın¬cı 84.1±10.5 mmHg iken tedavi ile 76.9 ±8.5mınHg (p<0.05) değerine düştü. Çalışma süresince hastaların glukolize hemoglobin ve lipid profilleri sabit kaldı, be¬lirgin metabolik değişiklik olmadı. Plazma renin aktivi-tesi çalışma başlangıcında 1,97+2.3 ng/ml/saat, çalış¬ma sonunda 6.40 + 8.98ng/ml/saat ve kontrolgrubun¬da 3.44±2.52ng/ml/saat olarak ölçüldü, her ölçüm arasında istatistiksel farklılık yoktu. Plazma endotelin düzeyi çalışma başlangıcında 7.55 + 7.82 pmol/ml bu¬lundu ve bu değer kontrol grubunda 14.39 + 6.01 pmol/ml ölçüldü, aradaki fark anlamlıydı (p<0.01). Çalışma sonunda ölçülen endotelin düzeyi 9.20+4.34 pmol/ml ise başlangıç değerlerine ve kontrol grubuna göre istatistiksel fark taşımıyordu. Sonuç olarak Tip 2 Diabetik hastalarda mikroalbüminüri döneminde plaz¬ma endotelin düzeyleri düşük bulunmuştur, enalapril tedavisi ile mikroalbüminüri belirgin olarak azaldığı halde endotelin 1 düzeyinde değişiklik olmaması dia-betik nefropati patofızyolojisinde endotelinin belirgin rolünün olmadığını düşündürmektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_54.pdf
  • 2
70-75
  • Turkish

REFERENCES

References: 

1 - Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Dec-
kert T:
Diabeti
c nephropathy in type 1 (insulin-dependent) diabetes: An epidemiologic study. Diabetlogia 25:496-501, 1983
2 - Krolewski AS, Warram JA, Christlieb AR, Busick EI, Kahn
JR: The changing natural history of nephropathy in type 1 di¬abetes, Am J Med 78:785-794, 1985
3 - Ballard DJ, Humprey LL, Melton LJ, Frohnert PP, Chu CP,
et al: Epidemiology of persistant proteinuria in type II diabe¬tes mellitus, Diabetes 37:405-412, 1988
4 - Vora JP, Dolben J, Dean JD, Thomas D, Williams JD, et al:
Renal hemodynamics in newly presenting non-insulin depen¬dent diabetes mellitus. Kidney Int41: 829-835, 1992
5 - Rudberg S, Persson B, Dahlquist G: Increased glomerular fil¬
tration rate as a predictor of diabetic nephropathy- An 8 year
procpective study. Kidney Int41:822-828, 1992
6 - Anderson S, Brenner BM: Pathogenesis of diabetic glomerulo-
pathy: Hemodynamic considerations. Diabetes/Metabolism Rew 4:163-177, 1988
7 - Noth RH, Krolewski AS, Kaysen GA, Meyer TW, Scambelan
M: Diabetic nephropathy:Hemodynamic basis and implicati¬ons for disease management Ann Int Med 110:795-813, 1989
8 - Reddi AS, Camerini-Davalos RA: Diabetic nephropathy: An
update. Arch Int Med 150:31-43, 1990
9 - Valentino VA, Wilson MD, Weart W, Bakris GL: A perspecti¬
ve on converting enzyme inhibitors and calcium channel anta¬gonists in diabetic renal disease. Arch Int Med 151:2367-2372,
1991
10 - Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, et al:
Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 293:471-474, 1986
11 - Dominguez JR, Calle H, Hurtado A, Robles RG, Sancho-Rof
J: Effect of converting enzyme inhibitors in hypertensive pati¬ents with non-insulin dependent diabetes mellitus. Postgradu¬ate Med j 62:66-68, 1986
12 - Rudberg S, Aperia A, Freyschuss U, Persson B: Enalapril re¬
duces microalbuminuria in young normotensive type 1 (insu¬lin-dependent) diabetic patients irrespective of its hypotensive
effect. Diabetologia 33:470-476, 1990
13 - Björck S, Mulec H, Johnsen S, Norden G, Aurell M: Renal
protective effect of enalapril in diabetic nephropathy. BMJ
304:339-343, 1992
14- Ravid M, Savin H, Jutrin I, Bental T, Katz B, et al: Long
term stabilizing effect of angiotensin convertin enzyme inhibiti¬on on plasma creatinine and on proteinuria in normotensive ty¬pe II diabetic patients. Ann Int Med 118:577-581, 1993 15- Ka-siske BL, Kalil RSN, MaJS, Liao M, Keane WF: Effect of an-
tihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Int Med 118:129-138, 1993 16 - Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
Nature (Lond.) 332:411-415, 1988
17 - Inowe A, Yanagisawa M, Kimura S, et al: The human endot-
helin family: Three structurally and pharmacologically district isopeptides predicted by three seperate genes. Proc. Natl.
Acad Sci USA 86:2863-2867, 1989
18 - Kohno M, Yasanuri K, Murakawa K, et al: Plasma immunore-
active endothelin in essential hypertension Am JMed
88:614-618, 1990
19 - Koyama H, Tabata T, Nishisawa Y, et al: Plasma endothelin
levels in patients with uremia. Lancet i:991-992,1989
20 - Miyauchi T, Yanagisawa M, Tomisawa T, et al: Increased plas¬
ma concentration of endothelin 1 and big endothelin 1 in acute myocordial infarction. Lanceti ii:53-54, 1989
21 - Cernacek P. Stewart DJ: Immunoreactive endothelin in hu¬
man plasma: Marked elevation in patients in cardiogenic shock. Biochem Biophys Res Common 161:562-567, 1989
22 - Underwood D, Aarhus L, Heublein D, Burnett JC: Endothe-
lin in thoracic inferior vena caval constriction. Am J Physiol
263: H951-H958, 1992
23 - Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom
SR: Elevated plasma endothelin in patients with diabetes melli-
tus. Diabetologia 33:306-310, 1990
24 - Collier A, Leach JP, Mclennan A, Jardine A, Morton JJ, et al:
Plasma endothelinlike immunoreactivity levels in IDDM pati¬ents with microalbuminaria. Diabetes Care 15:1038-1040, 1992
25 - Rubin SA, Levin ER: The endocrinology of vasoactive pepti-
des, Synthesis to function. J Clin End Met 78:6-10, 1994
26 - Schankert H, Ingelfinger JR, Dzau VJ: Evolving concepts of
the intrarenal reninangiotensin system in health and disease: Contributions of molecular biology. Renal Physiol Biochem 14:146-154,1991
27 - Griendling KK, Murphy JJ, Alexander RW: Molecular bio¬
logy of renin-angiotensin system. Circulation 87:1816-1828,
1993
28 - Sigmund CD, Jones CA, Kane CM, et al: Regulated tissue
and cell specific expression of the human renin gene in transge-
nic mice. Circ Res 70:1070-1079, 1992
29 - Johns DW, Peach MJ, Gomez RA, et al: Angiotensin II regu¬
lates renin gene expression. Am J Physiol 259:F882-F887, 1990
30 - Jaffa AA, Chai KX, Chao J, et al: Effects of diabetes and insu¬
lin on expression of kalkrein and renin genes in the kidney.
Kidney Int41:789-795,»1992
31- Correa-Rotter R, Hosttetter TH, Rosenberg ME:Renin and angiotensin gene expression in experimental diabetes .mellitus
(Kidney Int41:796-804, 1992
32 - Murakawa K, Kohno M, Yukokawa K, et al: Endothelin indu¬
ced renal vasoconstriction and increase in cytosolic calcium in renal vascular smooth muscle cells. Clin Exp Hypertens A12:1037-1048, 1990
33 - Murakawa K, Kohno M, Yukokawa K, et al: Endothelin indu¬
ced renal vasoconstriction and increase in cytosolic calcium in renal vascular smooth muscle cells. Clin Exp Hypertens A12:
1037 -1048, 1990
34 - Marsden PA, Danthuluri NR, Brenner BM, et al: Endothelin
action on vascular smooth muscle involves inositol triphospha-te and calcium mobilization. Biochem Biophys Res Common 158:86-93,1-989
35 - Nurez DJ, Brown MJ, Davenport AP, et al: Endothelin lmR-
NA is widely expressed in porcine and human tissues. J Clin In¬vest 85:1537-1541, 1990
36 - Sakamato J, Sakai S, Hirata Y, et al: Production of endothe-
lin 1 by rat cultured mesangial cells. Biochem Biophy Res
Common 169:462-468, 1990
37- Kohno M, HorioT, Ikeda M,*et al: Angiotensin II stimulates
74
endothelin
1
secretion in cultured rat mesangial cells. Kidney 46 - Veglio F, Bertello P, Pinna G, et al: Plasma endothelin in es-
Int 42:860-866, 1992 sential hypertension and diabetes mellitus. J Hum Hypertens
38 - Bakris G, Fairbanks R, Traish AM: Argine vasopressin stimu- 7:321-325, 1993
lates human mesangial cell production of endothelin. J Clin In- 47- Gruden G, Cavallo-Perin P, Bazzan M, et al: PAI-1 and fac-
vest 87:1158-1164, 1991 tor VII activity are higher in IDDM patients with microalbumi-
39 - Sijonmaa O, Ristimaki A, Fyhrquist F: Atrial natriuretic pepti- nuira. Diabetes 43: 426-429, 1994
de, nitroglycerine and nitroprusside reduce basal and stimula- 48 - Totsune K, Sone M, Takahashi K, et al: Immunoreactive en-
ted endothelin production from cultured endothelial cells. Bi- dothelin in urine of patients with and without diabetes melli-
ochem Biophys Res Commun 173:514-520, 1990 tus. J Cardiovasc Pharmacol 17:S423-S424, 1991
40 - Simonson MS, Wann S, Mene P, et al: Endothelin stimulates 49 - Fernandez-Cruz A, Martin P, Fernandez L, et al: Plasma en-
phospholipase C, Na/H exchange, C-fos expression and mito- dothelin is increased in young essential hypertensives but not
genesis in rat mesangial cells. J Clin Invest 83:708-712, 1989 in elderly essential or diabetic hypertensives. J Hypertens
41 - Sugiara M, Snaydar RM, Scwartzberg M, et al: Identification Suppl 11:S146-S147, 1993
of two types of specific endothelin reseptors in rat mesangial 50 - Tsunoda K, Abe K, Sato T, et al: Decreased conversion of big
cell. Biochem Biophys Res Commun 161:1396-1401,1989 endothelin 1 to endothelin 1 in patients with diabetes mellitus.
42 - Badi KF, Murray JJ, Breyer MD, et al: Mesangial cell, glome- Clin Exp Pharmacol Physiol 18:731-732, 1991
rular and renal vascular responses to endothelin in the rat kid- 51 - Golfman LS, Hata T, Beamish RE, Dhalla NS: Role of endot-
ney: Elucidation of signal transduction pathways. J Clin Invest helin in heart function in health and disease. Can J Cardiol
83:336-342, 1989 9:635-653, 1993
43 - Kawamura M, Ohgawara H, Naruse M, et al: Increased plas- 52 - Cohen RA: Dysfunction of vascular endothelium in diabetes
ma endothelin in NIDDM patients with retinopathy. Diabetes mellitus. Circulation 87:V67-V76, 1993
Care 15:1396-1397, 1992 53 - Parving HH, Kastrup H, Smith VM, et al: Impaired autoregu-
44 - Haah T, Jungmann E, Felber A, et al:Increased plasma levels [ation of glomerular filtration rate of type 1 (insulin-depen-
of endothelin in diabetic patients with hypertension. Am J Hy- dent) diabetic patients with nephropathy. Diabetologia
pertens 5:161-166, 1992 27:547-552, 1984
45 - Kanno K, Hirata Y, Shichiri M, Marumo F: Plasma endothe- 54 - Sharekin J, Diamond J, Eshin S, et al: Fluid flow decreases
lin 1 levels in patients with diabetes mellitus with or without preproendothelin mRNA levels and suppresses endothelin 1
vascular complication. J Cardiovasc Pharmacol 17:S475-S476, peptide release in cultured human endothelial cells. J Vase
1991 Surg 14:1-9, 1991
75

Thank you for copying data from http://www.arastirmax.com